Bavarian Nordic — Marts 2017
-
Colique salget er naturligvis afgørende, og noget som kan sende aktien pænt højt. men vi hører nok først nærmere ved Q1, men lad os håbe der kommer noget nyt imorgen.
-
*soliqua
-
Videnskabelig artikel om ebolaforsøget der er blevet omtalt i medierne idag.
http://jamanetwork.com/journals/jama/article-abstract/2610324?resultClick=1 -
-
-
Regnskab fra Bava: https://play.borsen.dk/social/58c6815c45628ff8171fe1ee
-
Revenue of DKK 399 million is expected
from recognition of the upfront
payment received from Bristol Myers
Squibb (BMS) as part of the global license
option for PROSTVAC. This is based
upon the assumption that we provide
BMS with top-line PROSPECT (Phase 3)
data in the second half of 2017. -
OHW - Det er vel OK, når betalingen falder i det øjeblik data leveres til BMS?
-
BAVA inkluderer ikke betaling fra BMS på milepæl for at nå det krævede resultat på +4 måneders længere levetid til Prostvac patienter vs placebogruppen.
-
Ja sådan forstår jeg det.
-
ja, sådan opfatter jeg det også
-
Ja, det er dog lidt underligt, da der som forventet
intet nyt er i regnskabet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind